AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19158129 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise at 50% VO(2max) for 60 min
Number of subjects: 14
Study 19158129 — intervention group
Group type: COMPARATOR
Intervention: Rest for 60 min
Number of subjects: 14
Study 17410435 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalazine, 800 mg bid
Number of subjects: 268
Study 17410435 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalazine, 400 mg bid
Number of subjects: 268
Study 17410435 — intervention group
Group type: COMPARATOR
Intervention: rifaximin, 200 mg bid
Number of subjects: 268
Study 17410435 — intervention group
Group type: COMPARATOR
Intervention: rifaximin, 400 mg bid
Number of subjects: 268
Study 15628774 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep needling to trigger points
Number of subjects: 35
Study 15628774 — intervention group
Group type: COMPARATOR
Intervention: Standard acupuncture
Number of subjects: 35
Study 15628774 — intervention group
Group type: COMPARATOR
Intervention: Superficial needling to trigger points
Number of subjects: 35
Study 11529449 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, transitional acute care emphasizing home-based counseling and support, 24-hour rapid response, rural outreach, and intensive support management.
Number of subjects: 182
Study 11529449 — intervention group
Group type: COMPARATOR
Intervention: Routine care control group.
Number of subjects: 182
Study 9397285 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (irrelevant decision balance sheet)
Number of subjects: 0
Study 9397285 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (relevant decision balance sheet)
Number of subjects: 0
Study 9397285 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 0
Study 7955976 — intervention group
Group type: COMPARATOR
Intervention: Self-report compliance
Number of subjects: 424
Study 7955976 — intervention group
Group type: COMPARATOR
Intervention: Personality and intelligence variables
Number of subjects: 424
Study 7955976 — intervention group
Group type: COMPARATOR
Intervention: Age and duration of diabetes
Number of subjects: 424
Study 7955976 — intervention group
Group type: COMPARATOR
Intervention: Onset-age of diabetes
Number of subjects: 424
Study 7955976 — intervention group
Group type: COMPARATOR
Intervention: Personality variables
Number of subjects: 424
Study 3593994 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (0.1 mg X kg‐1 i.v.)
Number of subjects: 11
Study 3593994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30297759 — intervention group
Group type: EXPERIMENTAL
Intervention: Oats soaked overnight in skim milk (ONO)
Number of subjects: 80
Study 30297759 — intervention group
Group type: EXPERIMENTAL
Intervention: Oats soaked overnight in skim milk with sugar, nuts, and seeds (ONOsns)
Number of subjects: 80
Study 30297759 — intervention group
Group type: COMPARATOR
Intervention: Cooked cream of rice cereal (CR)
Number of subjects: 80
Study 30297759 — intervention group
Group type: COMPARATOR
Intervention: Cooked cream of rice cereal with sugar, nuts, and seeds (CRsns)
Number of subjects: 80
Study 28575891 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated chest compressions
Number of subjects: 12
Study 28575891 — intervention group
Group type: COMPARATOR
Intervention: Manual chest compressions
Number of subjects: 12
Study 26081100 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg CoQ10 twice daily for 1 week
Number of subjects: 20
Study 26081100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23605473 — intervention group
Group type: EXPERIMENTAL
Intervention: Assets‐Getting To Outcomes (AGTO) intervention
Number of subjects: 32
Study 23605473 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-users of AGTO)
Number of subjects: 32
Study 23605473 — intervention group
Group type: EXPERIMENTAL
Intervention: AGTO intervention programs
Number of subjects: 32
Study 23605473 — intervention group
Group type: EXPERIMENTAL
Intervention: AGTO intervention
Number of subjects: 32
Study 21270793 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 16
Study 19465123 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg capsules in the fed state
Number of subjects: 0
Study 19465123 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200mg capsules in the fasted state
Number of subjects: 0
Study 17072271 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated vaccination program (day 0, 10, 21)
Number of subjects: 0
Study 17072271 — intervention group
Group type: COMPARATOR
Intervention: Classical vaccination program (day 0, 30, 60)
Number of subjects: 0
Study 15063888 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (nurse called participants)
Number of subjects: 469
Study 15063888 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (participants called themselves)
Number of subjects: 469
Study 15063888 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy procedure
Number of subjects: 469
Study 15063888 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall experience of flexible sigmoidoscopy
Number of subjects: 469
Study 15063888 — intervention group
Group type: EXPERIMENTAL
Intervention: Failures in examination
Number of subjects: 469
Study 10776222 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam mattress (TheraRest)
Number of subjects: 120
Study 10776222 — intervention group
Group type: COMPARATOR
Intervention: Water mattress (Secutex)
Number of subjects: 120
Study 8676529 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt discontinuation of TPN
Number of subjects: 21
Study 8676529 — intervention group
Group type: COMPARATOR
Intervention: Tapering of TPN (decreasing infusion rate by 50% for 1 hour before discontinuation)
Number of subjects: 21
Study 1373535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA)
Number of subjects: 140
Study 1373535 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 (FK)
Number of subjects: 140
Study 1373535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA) with OKT3
Number of subjects: 140
Study 1373535 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 (FK) with OKT3
Number of subjects: 140
Study 6475824 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic iron, 920 mumol (51 mg)
Number of subjects: 0
Study 6475824 — intervention group
Group type: EXPERIMENTAL
Intervention: HB iron, 480 mumol (26 mg)
Number of subjects: 0
Study 6475824 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic iron, 610 mumol (34 mg)
Number of subjects: 0
Study 6475824 — intervention group
Group type: EXPERIMENTAL
Intervention: Tin, 306 mumol (36 mg)
Number of subjects: 0
Study 6475824 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper, 79 mumol (5 mg)
Number of subjects: 0
Study 31106336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) defibrillating device
Number of subjects: 0
Study 31106336 — intervention group
Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT) pacer
Number of subjects: 0
Study 31106336 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT in patients with wide QRS (>150 ms)
Number of subjects: 0
Study 31106336 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT in patients with narrow QRS (<130 ms)
Number of subjects: 0
Study 28573672 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMO CBT
Number of subjects: 855
Study 28573672 — intervention group
Group type: COMPARATOR
Intervention: MEMO Control
Number of subjects: 855
Study 25909608 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgin
Number of subjects: 112
Study 25909608 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexalgin
Number of subjects: 112
Study 25909608 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 112
Study 25909608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 23677249 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin melt (120/240 μg)
Number of subjects: 221
Study 23677249 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin tablet (0.2/0.4 mg)
Number of subjects: 221
Study 21843943 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly nab-paclitaxel (150 mg/m2)
Number of subjects: 114
Study 21843943 — intervention group
Group type: COMPARATOR
Intervention: q3w nab-paclitaxel
Number of subjects: 114
Study 21843943 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 114
Study 21843943 — intervention group
Group type: COMPARATOR
Intervention: Solvent-based paclitaxel
Number of subjects: 114
Study 19631353 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycemic index/glycemic load diet
Number of subjects: 24
Study 19631353 — intervention group
Group type: COMPARATOR
Intervention: Low-glycemic index/glycemic load diet
Number of subjects: 24
Study 17277647 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild water-filtered near infrared whole-body hyperthermia (NI-WBH) plus multimodal rehabilitation (MR)
Number of subjects: 139
Study 17277647 — intervention group
Group type: COMPARATOR
Intervention: Multimodal rehabilitation (MR) only
Number of subjects: 139
Study 17277647 — intervention group
Group type: EXPERIMENTAL
Intervention: NI-WBH plus MR
Number of subjects: 139
Study 17277647 — intervention group
Group type: COMPARATOR
Intervention: MR only
Number of subjects: 139
Study 15142029 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg(2+)-Cr group (2.5 g of Cr daily)
Number of subjects: 31
Study 15142029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr group (2.5 g of Cr daily)
Number of subjects: 31
Study 15142029 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (multidextran)
Number of subjects: 31
Study 12074415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.2% with fentanyl 2 microg mL(‐1)
Number of subjects: 60
Study 12074415 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2% with fentanyl 2 microg mL(‐1)
Number of subjects: 60
Study 10189118 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence technique for evaluating baroreflex sensitivity (BRS)
Number of subjects: 0
Study 10189118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-spectral technique for evaluating baroreflex sensitivity (BRS)
Number of subjects: 0
Study 10189118 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence technique (activating sequence)
Number of subjects: 0
Study 10189118 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence technique (deactivating sequence)
Number of subjects: 0
Study 7598090 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐minute sports massage of the lower extremities
Number of subjects: 10
Study 7598090 — intervention group
Group type: COMPARATOR
Intervention: Control Session (motionless for 30 minutes)
Number of subjects: 10
Study 2240994 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/day)
Number of subjects: 36
Study 2240994 — intervention group
Group type: COMPARATOR
Intervention: Betahistine (24 mg/day)
Number of subjects: 36
Study 7372228 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg digoxin b.i.d.
Number of subjects: 23
Study 7372228 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg digoxin b.i.d.
Number of subjects: 23
Study 7372228 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg beta-methyl-digoxin b.i.d.
Number of subjects: 23
Study 6386561 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (NST, OCT, serum unconjugated estriol measurements, ultrasound measurement of H/A c.r.)
Number of subjects: 306
Study 6386561 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (NST, OCT, ultrasound measurement of H/A)
Number of subjects: 306
Study 6386561 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A
Number of subjects: 306
Study 6386561 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum free estriol measurements
Number of subjects: 306
Study 6386561 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive pregnancy management without serum free estriol measurement
Number of subjects: 306
Study 30507228 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 70
Study 30507228 — intervention group
Group type: COMPARATOR
Intervention: Sham Control
Number of subjects: 70
Study 28071011 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LC)
Number of subjects: 77
Study 28071011 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric diet plus metformin (IM)
Number of subjects: 77
Study 28071011 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 77
Study 23941272 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming randomness
Number of subjects: 134
Study 23941272 — intervention group
Group type: COMPARATOR
Intervention: Priming negativity
Number of subjects: 134
Study 23941272 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 134
Study 22282104 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate II (HMII) destination therapy (DT)
Number of subjects: 414
Study 20034967 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 1.5%
Number of subjects: 20
Study 18355402 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy plus systemic therapy (cyclophosphamide, methotrexate, and fluorouracil for premenopausal women; tamoxifen for postmenopausal women)
Number of subjects: 3083
Study 18355402 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy alone
Number of subjects: 3083
Study 15845701 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cells stored <8 days
Number of subjects: 66
Study 15845701 — intervention group
Group type: COMPARATOR
Intervention: Standard red cells
Number of subjects: 66
Study 12578439 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate
Number of subjects: 0
Study 12578439 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of methylphenidate (3 times daily)
Number of subjects: 0
Study 10561294 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy to the breast (XRT group)
Number of subjects: 381
Study 10561294 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (non‐XRT group)
Number of subjects: 381
Study 8961310 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice condition
Number of subjects: 30
Study 8961310 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked-Random practice condition
Number of subjects: 30
Study 8961310 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice condition
Number of subjects: 30
Study 1762298 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical povidone-iodine ointment (T)
Number of subjects: 129
Study 7050047 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic irradiation (175 rad every other day to a total of 525 rad)
Number of subjects: 64
Study 7050047 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 64
Study 31869451 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose gabapentin (2700 mg daily) with standard care (hydrocodone and/or acetaminophen progressing to fentanyl as needed)
Number of subjects: 60
Study 31869451 — intervention group
Group type: COMPARATOR
Intervention: Low-dose gabapentin (900 mg daily) with methadone
Number of subjects: 60
Study 30343354 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral saffron supplementation (20 mg/day) for 3 months
Number of subjects: 100
Study 30343354 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral saffron supplementation (20 mg/day) for 3 months among participants on AREDS supplements
Number of subjects: 100
Study 30343354 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 100
Study 28803704 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded activity exercises
Number of subjects: 66
Study 28803704 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy-based exercises
Number of subjects: 66
Study 26813634 — intervention group
Group type: EXPERIMENTAL
Intervention: Running with a familiar peer
Number of subjects: 24
Study 26813634 — intervention group
Group type: EXPERIMENTAL
Intervention: Running with an unfamiliar peer
Number of subjects: 24
Study 26813634 — intervention group
Group type: COMPARATOR
Intervention: Running alone
Number of subjects: 24
Study 24788102 — intervention group
Group type: EXPERIMENTAL
Intervention: Racotumomab-alum (5 immunizations every 2 weeks and re-immunizations every 4 weeks)
Number of subjects: 176
Study 24788102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 21594233 — intervention group
Group type: EXPERIMENTAL
Intervention: Silane/adhesive/Variolink II
Number of subjects: 80
Study 21594233 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia primer/Multilink Automix
Number of subjects: 80
Study 21594233 — intervention group
Group type: COMPARATOR
Intervention: Thermocycling
Number of subjects: 80
Study 21594233 — intervention group
Group type: COMPARATOR
Intervention: Non-glazed groups
Number of subjects: 80
Study 21594233 — intervention group
Group type: COMPARATOR
Intervention: Glazed groups
Number of subjects: 80
Study 19292787 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PUVA
Number of subjects: 29
Study 19292787 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath PUVA
Number of subjects: 29
Study 19292787 — intervention group
Group type: COMPARATOR
Intervention: Both PUVA modalities
Number of subjects: 29
Study 17686343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic monoclonal antibodies (MAbs)
Number of subjects: 0
Study 17686343 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Campath‐1H®)
Number of subjects: 0
Study 16043407 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate 50 mg bid
Number of subjects: 51
Study 16043407 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg bid
Number of subjects: 51
Study 11589868 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol (Cosopt)
Number of subjects: 15
Study 11589868 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 15
Study 9727377 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma pentosidine levels in diabetic patients
Number of subjects: 0
Study 9727377 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma pentosidine levels in patients with normal renal function
Number of subjects: 0
Study 9727377 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of hypertension
Number of subjects: 0
Study 9727377 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ischemic heart disease
Number of subjects: 0
Study 9727377 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 0
Study 8071837 — intervention group
Group type: EXPERIMENTAL
Intervention: BOF-4272 100 mg
Number of subjects: 14
Study 8071837 — intervention group
Group type: EXPERIMENTAL
Intervention: BOF-4272 200 mg
Number of subjects: 14
Study 8071837 — intervention group
Group type: EXPERIMENTAL
Intervention: BOF-4272 400 mg
Number of subjects: 14
Study 8071837 — intervention group
Group type: EXPERIMENTAL
Intervention: BOF-4272 200 mg (multiple-dose)
Number of subjects: 14
Study 8071837 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single-dose)
Number of subjects: 14
Study 8071837 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multiple-dose)
Number of subjects: 14
Study 2485283 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse prevention (RP) program emphasizing cognitive‐behavioral coping skills
Number of subjects: 0
Study 2485283 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad spectrum (BS) program emphasizing behavioral skills
Number of subjects: 0
Study 2485283 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 30937510 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Enhancement and Cognitive Therapy (NECT)
Number of subjects: 170
Study 30937510 — intervention group
Group type: COMPARATOR
Intervention: Supportive group therapy
Number of subjects: 170
Study 25349051 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education intervention in two sessions
Number of subjects: 60
Study 25349051 — intervention group
Group type: COMPARATOR
Intervention: Routine education (Control)
Number of subjects: 60
Study 25692310 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg QD via Respimat®
Number of subjects: 3104
Study 25692310 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg QD via Respimat®
Number of subjects: 3104
Study 25692310 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg BID via Aerolizer®
Number of subjects: 3104
Study 25692310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3104
Study 24153053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention A: Training in communication skills and providing graphic feedback about glycosylated haemoglobin levels.
Number of subjects: 0
Study 24153053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention B: Training in communication skills, providing graphic feedback about glycosylated haemoglobin levels, and additional telephone reinforcement.
Number of subjects: 0
Study 24153053 — intervention group
Group type: COMPARATOR
Intervention: Control group: Usual care provided by General Practitioners.
Number of subjects: 0
Study 24153053 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control): Secondary outcome measures include blood pressure, lipidemia, body mass index, and waist circumference.
Number of subjects: 0
Study 21145258 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day plus placebo (ATV+PLA)
Number of subjects: 74
Study 21145258 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day plus allopurinol 300 mg/day (ATV+ALLO)
Number of subjects: 74
Study 20102063 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX) as an irrigant
Number of subjects: 44
Study 20102063 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 44
Study 16773859 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive assessment followed by treatment
Number of subjects: 0
Study 16773859 — intervention group
Group type: COMPARATOR
Intervention: Treatment without assessment
Number of subjects: 0
Study 16773859 — intervention group
Group type: COMPARATOR
Intervention: Repetitive use of ineffective treatments
Number of subjects: 0